Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pragmatic randomised trial of risperidone long acting injection versus oral atypical antipsychotics in poorly adherent subjects with schizophrenia in a routine care setting.

Trial Profile

Pragmatic randomised trial of risperidone long acting injection versus oral atypical antipsychotics in poorly adherent subjects with schizophrenia in a routine care setting.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Risperidone (Primary) ; Amisulpride; Antipsychotics; Aripiprazole; Olanzapine; Quetiapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms PRAGMATIC
  • Sponsors Janssen Inc
  • Most Recent Events

    • 07 Jul 2009 Actual number of patients (169) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Planned end date added as 1 Apr 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top